<DOC>
	<DOC>NCT00625248</DOC>
	<brief_summary>This study will evaluate bleeding risk and differences in outcomes in patients receiving and not receiving anticoagulant or antiplatelet therapy</brief_summary>
	<brief_title>Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy</brief_title>
	<detailed_description>1. To evaluate bleeding risk in interventional procedures in patients with or without antiplatelet and/or anticoagulant therapy. 2. To evaluate differences in outcomes in patients not receiving any anticoagulant or antiplatelet therapy compared to patients receiving various types of drugs with anticoagulant or antiplatelet therapeutic effects. 3. To evaluate and compare the adverse event profiling all patients.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Subjects undergoing interventional techniques. Subjects who were able to give voluntary, written informed consent. All those things, patients on heparin, dextran, and low molecular heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>